282 related articles for article (PubMed ID: 35604836)
21. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD
Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
[TBL] [Abstract][Full Text] [Related]
22. Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.
Wei B; Braun TM; Tamura RN; Kidwell K
J Biopharm Stat; 2020 Nov; 30(6):1109-1120. PubMed ID: 32892710
[TBL] [Abstract][Full Text] [Related]
23. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
24. Bayesian basket trial design with false-discovery rate control.
Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
[TBL] [Abstract][Full Text] [Related]
25. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
Hampson LV; Whitehead J; Eleftheriou D; Brogan P
Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
[TBL] [Abstract][Full Text] [Related]
26. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
Xu T; Shi H; Lin R
Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Adult Data in Designing Pediatric Pharmacokinetic Studies: How Much Are Historical Adult Data Worth?
Hsu CH; Steven Xu X; Wang J; Zhang L; Liu C; Wang Y
J Clin Pharmacol; 2019 Jul; 59(7):989-996. PubMed ID: 30748023
[TBL] [Abstract][Full Text] [Related]
28. Exact sample size determination for a single Poisson random sample.
Gentile S; Sambucini V
Biom J; 2023 Oct; 65(7):e2200183. PubMed ID: 37160700
[TBL] [Abstract][Full Text] [Related]
29. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
30. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
[TBL] [Abstract][Full Text] [Related]
31. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
Harari O; Soltanifar M; Verhoek A; Heeg B
Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
[TBL] [Abstract][Full Text] [Related]
32. Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types.
Jin J; Riviere MK; Luo X; Dong Y
Stat Med; 2020 Nov; 39(25):3459-3475. PubMed ID: 32717103
[TBL] [Abstract][Full Text] [Related]
33. Bayesian sample size determination using commensurate priors to leverage preexperimental data.
Zheng H; Jaki T; Wason JMS
Biometrics; 2023 Jun; 79(2):669-683. PubMed ID: 35253201
[TBL] [Abstract][Full Text] [Related]
34. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
Harun N; Liu C; Kim MO
Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
[TBL] [Abstract][Full Text] [Related]
35. A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.
Calderazzo S; Wiesenfarth M; Kopp-Schneider A
Biostatistics; 2022 Jan; 23(1):328-344. PubMed ID: 32735010
[TBL] [Abstract][Full Text] [Related]
36. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
Bi D; Liu M; Lin J; Liu R
Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
[TBL] [Abstract][Full Text] [Related]
37. Bayesian Design for Pediatric Clinical Trials with Binary Endpoints When Borrowing Historical Information of Treatment Effect.
Jin M; Li Q; Kaur A
Ther Innov Regul Sci; 2021 Mar; 55(2):360-369. PubMed ID: 32955713
[TBL] [Abstract][Full Text] [Related]
38. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
Zhang W; Pan Z; Yuan Y
J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
[TBL] [Abstract][Full Text] [Related]
39. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
Berry SM; Broglio KR; Groshen S; Berry DA
Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
[TBL] [Abstract][Full Text] [Related]
40. Robust incorporation of historical information with known type I error rate inflation.
Calderazzo S; Wiesenfarth M; Kopp-Schneider A
Biom J; 2024 Jan; 66(1):e2200322. PubMed ID: 38063813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
